Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript Summary
Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript Summary
The following is a summary of the Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript:
以下是Celcuity(爱文思控股)Q2 2024业绩会交流摘要:
Financial Performance:
金融业绩:
For Q2 2024, Celcuity reported a net loss of $23.7 million or $0.62 per share, compared from a net loss of $14.6 million or $0.66 per share in Q2 2023.
Non-GAAP adjusted net loss was $22.2 million or $0.58 per share for Q2 2024, compared to a non-GAAP adjusted net loss of $11.1 million or $0.51 per share in Q2 2023.
The company raised $129 million from equity and debt offerings to strengthen their balance sheet.
2024年Q2,Celcuity报告净损失2370万美元或每股0.62美元,相比之下,2023年Q2净损失为1460万美元或每股0.66美元。
2024年Q2,非GAAP调整后的净损失为2220万美元或每股0.58美元,相比之下,2023年Q2非GAAP调整后的净损失为1110万美元或每股0.51美元。
该公司通过股权和债务融资筹集了12900万美元,以增强其资产负债表。
Business Progress:
业务进展:
Celcuity has advanced the clinical development of gedatolisib with ongoing enrollment in key trials such as VIKTORIA-1 for advanced breast cancer and a trial for metastatic castration resistant prostate cancer.
Plans are in place for launching VIKTORIA-2 to evaluate gedatolisib as a first-line treatment for patients with HR+/HER2- advanced breast cancer.
Non-clinical research on gedatolisib was published, demonstrating its efficacy compared to single-node PI3K inhibitors in various cancer models.
Celcuity正在推进gedatolisib的临床开发,正在关键试验如面向晚期乳腺癌的VIKTORIA-1试验和转移性去势抵抗型前列腺癌的试验中进行招募。
已制定计划,计划启动VIKTORIA-2试验,评估gedatolisib作为HR+/HER2-晚期乳腺癌患者的一线治疗方案。
发表了gedatolisib的非临床研究,证明其在各种癌症模型中与单节点PI0.3万抑制剂相比的疗效。
Opportunities:
机会:
Celcuity expects to enroll about 638 subjects in the VIKTORIA-2 study, aimed at addressing the significant market of endocrine therapy resistant advanced breast cancer patients estimated at 15,000 to 20,000 annually in the US alone, potentially increasing the addressable market size for gedatolisib by up to $3 billion.
Celcuity预计在VIKTORIA-2研究中招募约638名受试者,以解决每年仅在美国被估计为15000至20000名、患有内分泌治疗耐药型晚期乳腺癌的患者的重要市场问题,可能将gedatolisib的可寻址市场规模增加至30亿美元。
Risks:
风险:
Projected shifts in the proportion of PIK3CA wild-type versus mutated patients in ongoing trials might impact the timing and outcomes of primary analysis events anticipated in late Q4 2024 to Q1 2025.
正在进行的试验中,PIK3CA野生型与突变型患者的比例预计发生变化,这可能会影响预计在2024年Q4末至2025年Q1期间预期的主要分析事件的时间和结果。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息,请参阅IR网站。本文只是为投资者提供参考,没有任何指导或推荐建议。